Merck & Co, J&J take Remicade rights battle to US arbitration
This article was originally published in Scrip
Executive Summary
Johnson & Johnson's dispute with Merck & Co over rights to the TNF-inhibitor Remicade (infliximab), and the follow-on agent Simponi (golimumab), is slated to go before an arbitration panel at the end of September.